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Glioblastoma represents the most common primary malignancy of the central nervous system in adults and remains a
largely incurable disease. The elucidation of disease subtypes based on mutational profiling, gene expression and DNA
methylation has so far failed to translate into improved clinical outcomes. However, new knowledge emerging from the
subtyping effort in the IDH-wild-type setting may provide directions for future precision therapies. Here, we review
recent learnings in the field, and further consider how tumour microenvironment differences across subtypes may
reveal novel contexts of vulnerability. We discuss recent treatment approaches and ongoing trials in the IDH-wild-
type glioblastoma setting, and propose an integrated discovery stratagem incorporating multi-omics, single-cell
technologies and computational approaches.
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INTRODUCTION
Glioblastoma (GBM) is the most common primary central
nervous system (CNS) malignancy in adults with an annual
incidence of 3 per 100 000.1 It is a heterogeneous disease
with a nearly universally fatal prognosis and, despite
aggressive treatment with surgical resection and adjuvant
chemo-radiotherapy, 85% of patients die within 2 years.
Resistance to conventional therapies is related to several
intrinsic properties of the tumour. For example, its diffuse
infiltrative nature makes complete resection impossible,
resulting in recurrence.2 Moreover, the disease is further
defined by microvascular proliferation, pseudopalisading
necrosis and overt intratumoural heterogeneity.2
Historically, GBM diagnosis was based on histology, and
classification limited to primary and secondary disease.3
However, the discovery of point mutations in genes
coding for the enzymes isocitrate dehydrogenase (IDH) 1
and 2 revolutionised the classification approach.4 IDH is a
metabolic enzyme that catalyses the oxidation of isocitrate
to alpha-ketoglutarate in the citric acid cycle5 (Figure 1). IDH
mutation status was incorporated into the revised World
Health Organization classification of brain tumours in 2016,6
thereby classifying GBM into two distinct entities: IDH-
mutant (IDH-mt) GBM and wild-type (IDH-wt) GBM,6
although further molecular assessment suggests that IDH-
mt GBMs align more closely with aggressive anaplastic
astrocytomas.7e9 As such, the Consortium to Inform Mo-
lecular and Practical Approaches to CNS Tumour Taxonomy
(cIMPACT-NOW) has proposed that the previously defined
IDH-mt GBM is now referred to as astrocytoma, IDH-mt,
grade IV. In addition, cIMPACT-NOW recommends the in-
clusion of CDKN2A/B homozygous deletion as a criterion for
grade IV, IDH-mt astrocytomas.10 In this review, we will
focus on IDH-wt GBM, which is often associated with single
copy loss of chromosome 10 and gain in chromosome 7.11
IDH-wt GBM manifests with significant interpatient differ-
ences and marked intratumoural heterogeneity. Additional
frequent features include amplification of receptor tyrosine
kinases such as epidermal growth factor receptor (EGFR)
and platelet-derived growth factor receptor A (PDGFRA),
mutations in telomerase reverse transcriptase (TERT)
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promotor and loss of the tumour suppressor gene phos-
phatase and tensin homolog (PTEN) (Figure 2). Interpatient
differences are observed at the genome, transcriptome12
and epigenetic level.4 Due to the heterogeneous nature of
GBM, homogenous treatment approaches have to date led
only to limited clinical advancement. It is thus clear that
knowledge gained from diverse molecular profiling should
direct future targeted therapeutic strategies. Here, we
consider new knowledge emerging from GBM subtyping
efforts, and reflect on how new learnings with respect to
molecular subtyping and tumour microenvironment (TME)
characteristics may provide hints towards new precision
targeting strategies.
MOLECULAR SUBTYPES
While classification based on IDH status supports the
elucidation of distinct categories of malignant brain tu-
mours, no novel therapeutic strategies have yet translated
to clinical benefit based on IDH status. Hence, efforts to
further stratify IDH-wt tumours are ongoing. Initial tumour
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Figure 1. IDH signalling pathway in IDH-wild-type versus IDH-mutant cells.
Unlike aberrant IDH-mutant intracellular signalling, wild-type IDH expression elicits no major effects on cellular metabolism, production of ROS, tumorigenesis or
proliferation. Cells expressing wild-type IDH favour a normal methylation pattern, compared with the favoured hypermethylation phenotype of IDH-mutant cells.
HIF, hypoxia-inducible factor; KG, ketoglutarate; ROS, reactive oxygen species.
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by Phillips et al.13 in 2006 showed that molecular classes
with enriched markers for proliferation, angiogenesis and
the mesenchyme were predictive of overall survival (OS)
and disease progression, with tumours commonly shifting
towards the mesenchymal subclass upon recurrence. In
2010, Verhaak et al.14 identified four discrete transcriptomic
subtypes of GBM: proneural, neural, mesenchymal and
classical (n ¼ 202 patients). Since then, the proneural
phenotype was shown to correspond more closely to IDH-
mt astrocytomas, younger age and secondary GBM. The
initial favourable prognosis observed in the proneural sub-
type was due to the inclusion of secondary GBM.14-16
Classical GBMs display high-level EGFR amplification (97%)
and few TP53 mutations, whereas mesenchymal GBMs are
underpinned by a high NF1 mutational burden.14 Following
emergence of the most recent classification of diffuse gli-
omas, and coupled with new data illustrating the influence
of TME on GBM subtyping,17 Wang et al.12 have now
further refined GBM IDH-wt molecular subtypes. This sub-
typing approach is based on tumour-intrinsic transcriptomic
signatures which are uniquely expressed by GBM tumour
cells and not by tumour-associated host cells. In this
context, three distinct subtypes have been shown to
correlate with proneural, classical and mesenchymal tu-
mours. The neural subtype was found to be largely
comprised of samples with low tumour content and thus
removed.18 Mutations in the TERT promoter have also been
identified as a prognostic marker in this setting.19 Specif-
ically, Killela et al.18 identified TERT promoter mutations
(TERT-mt) in 83% of primary IDH-wt GBMs and have
demonstrated that patients without the TERT mutation
survive longer than TERT-mt patients (27 versus 14 months).
DNA methylation is a key factor in defining GBM het-
erogeneity. Patterns of DNA methylation in tumour cells
play a significant role in defining the characteristics
inherent to each GBM subgroup.15,20,21 MGMT promoter
methylation is a well-known prognostic and predictive
factor associated with response to alkylating agents such
as temozolomide (TMZ).22 Indeed, integration of DNA
methylation with RNA expression profiles in adult gliomas
has revealed multiple novel glioma subgroups.4 Recent
work has established two methylation clusters in IDH-wt;
classic-like and mesenchymal-like (Figure 2). These clusters
are associated with disease grade and patient prognosis
and provide further insight into the impact of epigenetic
alterations on glioma progression. de Souza et al.8 carried
out a comprehensive DNA methylation longitudinal anal-
ysis of 200 gliomas from 77 patients. These analyses
determined epigenetic patterns of malignant trans-
formation from low to higher grade gliomas and identified
epigenetic alterations from the IDH-mt cytosine-phos-
phate-guanine (CpG) island methylator phenotype (G-
CIMP)-high subtype to the G-CIMP-low subtype which
mimics IDH-wt primary GBM. These epigenetic alterations
are predictive biomarkers for risk of malignant recurrence
at early stage disease.8 Notably, IDH-wt epigenetic profiles
did not significantly change upon recurrence. This study
underscores epigenetic profiling as a robust classifier of
GBM, which can identify key genetic alterations contrib-
uting to the aggressive IDH-wt phenotype. Additional
studies to fully identify the evolutionary patterns driving
these methylation changes are warranted.
Overall, molecular subtyping has made significant strides
towards the elucidation of an improved understanding of
































Figure 2. IDH-wild-type tumours are defined by distinct mutational and molecular features.
IDH-wt tumours harbour unique mutations which define molecular and transcriptomic subtypes, methylation subtypes, tumour purity.
amp., amplification; CDK4, cyclin-dependent kinase 4; CDKNA2, cyclin-dependent kinase inhibitor 2A; del., deletion; EGFR, epidermal growth factor receptor; GBM,
glioblastoma; LG-m6, TCGA Pan-glioma (LGm) DNA methylation cluster 6; MDM, murine double minute; NF1, neurofibromatosis type 1; PDGFR, platelet-derived growth
factor receptor; PTEN, phosphatase and tensin homolog; RB1, retinoblastoma 1; RTK, receptor tyrosine kinase; TP53, tumour protein p53; wt, wild-type.
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GBM heterogeneity. Nevertheless, these approaches have
not yet generated clear insights into pathway dependencies
which might be leveraged for the development of effective
targeted therapies. Thus, a deeper characterisation of sub-
type specific tumour biology is needed.
TME CHARACTERISTICS
The GBM microenvironment consists of heterogeneous
non-neoplastic cells, including glial cells, microglia, immune
cells, vascular cells, reactive astrocytes and endothelial cells,
in addition to various GBM cell subpopulations such GBM
stem cells (GSCs). These cell populations exist in several
niches and have varying interactions with heterogeneous
tumour cells.23 GSCs are capable of remodelling the TME24
and not only display different transcriptional and epigenetic
heterogeneity depending on which niche they are derived
from, but also interact between niches to leverage sup-
portive cell signalling mechanisms.23 Initial reports charac-
terising GSCs suggested that this subpopulation could
recreate heterogeneous tumours in a one-way hierarchical
manner responsible for recurrence. However, it has recently
become clear that GBMs are inherently plastic, and display
stem cell properties to varying degrees.25,26 GBM cell
populations therefore exhibit a dynamic heterogeneity and
plasticity, with tumour equilibrium affected both by genetic
background and microenvironmental cues such as oxygen
concentrations or therapeutic pressure. Certainly, the role
of tumour plasticity with respect to therapy resistance
warrants significant attention.
Relative to other tumours, GBM presents an immuno-
logical ‘cold’ phenotype, defined by a low abundance of
tumour-infiltrating lymphocytes (TILs).27 Tumour-associated
macrophages (TAMs) represent the most abundant
component of the non-tumoural GBM TME, and, as part of
the innate immune system, serve primarily to clear cellular
debris via phagocytosis. TAMs, derived from microglia,
resident brain macrophages and blood monocytes, are
highly immunosuppressive and primarily involved in antigen
presentation and cellular phagocytosis. It is noteworthy that
in GBM the previous dual categorisation into M1-
proinflammatory and M2-immunosuppressive macrophage
phenotype has proven to be over-simplistic and does not
provide a comprehensive representation of the complex
activation states observed.28 The degree to which macro-
phages infiltrate the tumour has been shown to correlate
with a more aggressive clinical course and reduced OS.29
Chen et al30 showed that macrophage-low patients (n ¼
130) display a greater OS compared with macrophage-high
IDH-wt patients (n ¼ 201). It was further shown that PTEN
mutation culminates in increased TAM infiltration in the
TME by up-regulation of the yes-associated protein 1 (YAP1)
gene and lysis oxidase (LOX) expression in response to PTEN
mutation. The resulting TAMs drive angiogenesis and glioma
cell homeostasis via secretion of secreted phosphoprotein/
osteopontin 1 (SPP1). The importance of TAM and SPP1 in
the TME was further demonstrated in vivo as LOX inhibition
reduced tumour growth in a GBM orthoxenograft model.30
TAMs were also associated with antiangiogenic therapy
resistance.31 Interestingly, single-cell RNA sequencing
(scRNA-Seq) analysis has also revealed increased expression
of the macrophage recruitment factor gene CSF1 in pro-
neural tumours. Inhibition of the CSF1 receptor (CSFR1),
widely expressed in myeloid cells, has therefore been
studied in transgenic models of proneural disease, and has
been shown to improve survival outcomes in preclinical
models.32 Unfortunately, despite the observed tumour
regression in animals, CSFR1 inhibitors failed to improve
survival in patients, suggesting that TAMs acquire resistance
to CSFR1 inhibition.33,34 Nevertheless, efforts to re-
programme TAMs may prove important for eliciting
response to immune therapeutics in a subset of GBM pa-
tients.28 In particular, mesenchymal GBM has been shown
to exhibit highest TAM infiltration,35,36 with significant
macrophage content a histological signature of the subtype.
Thus, notwithstanding the lack of overall clinical benefit
observed to date, TAMs may yet represent a rational target
in the mesenchymal setting.32,36
Overall, the low abundance of TILs combined with the
profoundly immunosuppressive TME in IDH-wt GBM provides
major challenges for immunological treatments in this
setting.37 This aversive pro-neoplastic state is mediated
through several mechanisms including overexpression of
indoleamine 2,3-dioxygenase (IDO), production of interleukins
and impaired antigen presentation.38 Amankulor et al.39 have
identified differences in the infiltration of macrophages,
microglia, monocytes and neutrophils between grade IV, IDH-
mt astrocytomas and IDH-wt gliomas. IDH-wt GBM displays
significantly higher CD45þ immune cell infiltration, including
macrophages, dendritic cells, CD4 and CD8 T cells, microglia
and B cells, than grade IV, IDH-mt astrocytomas39,40 (Figure 3).
Polymorphonuclear cells (e.g. neutrophils) support extracel-
lular matrix (ECM) remodelling allowing tumour progression
and the establishment of new tumour vasculature.41 IDH-wt
tumours (specifically within the mesenchymal subtype) have
been shown to increase expression of immune checkpoint
proteins such as programmed cell death ligand 1 (PD-L1).42
This prevents stimulation of effector T cells, which impairs
the adaptive immune response. As these tumours exhibit a
diverse immune cell infiltrate and harbour a TME that may be
responsive to immunomodulating therapies, it is possible that
IDH-wt mesenchymal tumours could be more responsive to
combinatorial immune checkpoint inhibitor (ICI) treatment
strategies.43 For example, IDH-wt tumours display increased
expression of PD-L1 and simultaneously display a dual up-
regulation of STAT3 and mammalian target of rapamycin
(mTOR) pathways.44 A combinatorial immune therapy proto-
col with STAT3 ormTOR inhibition could potentiate the effects
of ICIs.
Wang et al.12 have also shown that IDH-wt GBM tran-
scriptional subtypes display variations in the immune
microenvironment. For example, the ESTIMATE computa-
tional tool, which infers stromal and immune cell presence
from expression data,12 reveals that the mesenchymal
subtype has a significantly reduced tumour purity (Figure 2)
compared with proneural and classical subtypes, with an
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increased abundance of macrophages, microglia and
neuroglia. Furthermore, the CIBERSORT45 in silico cytometry
method46 further established an up-regulation of tumour-
promoting, proinflammatory macrophage and neutrophil
gene signatures, and significantly reduced levels of the
natural killer cell gene signature in the mesenchymal sub-
type. These data suggest that IDH-wt GBM varies according
to transcriptional context, and that the immune contexture
is partially dependent on IDH status. It therefore seems
likely that IDH-wt tumours assigned to the mesenchymal
subtype could respond better to immunotherapy due to its
increased immune infiltrate, and might therefore be pri-
oritised for future clinical trials with a targeted ICI.47 In light
of the subtype-specific differences in immune contexture
discussed earlier, future trials may benefit further from a
stratified, ‘subtype-specific’ design.
IDH-wt TME
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Figure 3. The IDH-wild-type GBM TME is highly heterogeneous, pro-invasive and immunosuppressive.
IDH-wt GBM display high levels of CD45þ cell infiltration including high concentrations of microglia and macrophages, B-cells and T-cells. IDH-wt tumours display greater
VEGF, EGF, interferon (IFN)-g-inducible chemokines (e.g. CXCL10), CCL2 concentrations, and greater proliferative and invasive capacity than IDH-mt tumours.
CCL2, C-C motif chemokine ligand 2; CXCL10, C-X-C motif chemokine ligand 10; ECM, extracellular matrix; EGF, endothelial growth factor; GBM, glioblastoma; G-CSF,
granulocyte colony-stimulating factor; LOX, lysis oxidase; MMP, matrix metallopeptidases; mt, mutant; PD1, programmed cell death protein 1; PD-L1, programmed cell
death ligand 1; TAM, tumour-associated macrophage; TGF, transforming growth factor; TME, tumour microenvironment; VEGF, vascular endothelial growth factor;
wt, wild-type.
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INTRATUMOURAL HETEROGENEITY AND PLASTICITY
The evolution of new and effective precision treatment
strategies for IDH-wt GBM is hampered by considerable
intertumoural and intratumoural disease heterogeneity. A
study by Patel et al48 applied scRNA-Seq on five tumours
and identified distinct heterogeneous intratumoural
expression patterns between each GBM tumour. Moreover,
this analysis first identified that tumours contain multiple
and hybrid cell states according to classical, mesenchymal
and proneural signatures. This study further showed that
clinical outcome can be directly influenced by the propor-
tion of each cellular subtype within a tumour, and specif-
ically showed that greater intratumoural heterogeneity in
the proneural subtype is associated with reduced survival.48
GBM heterogeneity was further highlighted in a recent
study by Neftel et al.25 who identified four distinct and
dynamic cellular states in IDH-wt tumours, modulated by
both genetic drivers and the TME. It has been proposed
that these states define the developmental potential of the
tumour and intrinsic resistance to therapy. Specifically,
combining scRNA-Seq data from 28 tumours with The
Cancer Genome Atlas (TCGA) bulk data for 401 GBM
specimens, revealed that malignant cells can exist in four
reversible cellular states; neural-progenitor-like, oligoden-
drocyte-progenitor-like, astrocytic-like and mesenchymal-
like.25 These states may co-exist in individual tumours and
the equilibrium between states is influenced by genetic
alterations in CDK4, PDGFRA, EGFR and NF1, respectively.
The cycling capacity between states and inherent plasticity
further suggests that effective treatment hinges on target-
ing all four cellular states. Alternatively, cells might need to
be propelled into a single targetable state via selective
pressure on either the tumour or TME. Clearly, such intra-
tumoural heterogeneity and dynamic cellular plasticity has
significant implications on future therapeutic strategies in
this intractable setting.
TREATMENT APPROACHES IN IDH-WT GBM
A comprehensive review focused on the current manage-
ment of IDH-wt GBM with consideration also given to
future directions has recently been published.49
Kinase targeting
Kinase pathways represent an ostensibly valid therapeutic
target in GBM. EGFR is overexpressed in 60% of IDH-wt
GBMs,50 which is often combined with expression of EGFR
mutants or structural variants, whilst tumour suppressor
phosphatase and the tensin homolog (PTEN) gene is
mutated in 40% of cases.51 EGFR alterations include EGFR
amplifications which often coincide with the oncogenic
variant EGFRvIII. EGFRvIII functions to accelerate tumour
growth and proliferation,52 whereas PTEN-related dysregu-
lation of AKT/protein kinase B signalling cascade results in
dysregulated cellular proliferation and aberrant mTOR
activation.53
Early evidence therefore suggested that targeting PTEN,
mTOR and EGFR signalling cascades could hold promise;
however, this approach has thus far proved under-
whelming.54 These failures are exemplified when one con-
siders the limited clinical effects observed with the tyrosine
kinase inhibitors gefitinib, afatinib and lapatinib. Interven-
tion with these agents, while preventing dimerisation of
EGFR and thus inhibiting the receptor function, does not
block the aberrant signalling downstream of the receptor
and has yielded limited clinical benefit. For example, gefi-
tinib did not improve patient OS in a phase II trial in
recurrent GBM, or in a phase I/II trial in combination with
radiation in newly diagnosed GBM. Similarly, despite being
well tolerated in patients, afatinib and lapatinib have both
largely failed in the clinic with minimal antitumour activ-
ity.55-57 Furthermore, challenges associated with small
molecule targeting of EGFR were not overcome with
EGFRvIII targeting peptide vaccines. ACT IV, a large phase III
multicentre randomised, controlled trial (RCT)
(NCT01480479) showed no survival benefit upon the addi-
tion of rindopepimut, an EGFRvIII peptide vaccine, to
standard of care.58,59
Resistance to EGFR therapy was, until recently, explained
through positive signalling feedback, clonal evolution due to
therapeutic pressure and limited delivery of larger mole-
cules across the blood-brain barrier. More recently however,
Nathanson et al.52 have shown that the rate at which cells
recur with resistance following EGFR targeting therapy may
not be a result of classical clonal evolution.52 Circular,
extrachromosomal DNA (ecDNA) is employed by malignant
cells to increase oncogene copy number without chromo-
somal amplification, and drives tumour resistance
methods.60 Indeed, it has been proposed that GBM tu-
mours activate oncogenes through amplification of ecDNA,
rather than classical chromosomal alterations.61 These
oncogenic amplifications on ecDNA may also result in
increased tumour heterogeneity and contribute to accel-
erated tumour evolution.58 Indeed, Nathanson et al.52 show
that resistance to EGFR tyrosine kinase inhibitors occur via
elimination of mutant EGFR from circular, ecDNA. The
presence of an EGFRvIII mutation on ecDNA results in an
initial sensitivity to EGFR inhibition, however, upon with-
drawal of therapeutic pressure, clonal EGFRvIII mutations
rapidly re-emerge on this ecDNA, resulting in renewed
resistance to therapy. This would suggest that oncogenic
amplifications on ecDNA are essential in successful evasion
of targeted therapies, resulting in significant drug resis-
tance. Therefore, understanding the ecDNA mechanisms
that drive this therapeutic resistance is needed in order to
successfully target the oncogenic ecDNA amplifications in
GBM. This highlights the diversity and complexity of
mechanisms by which ecDNA promotes resistance in GBM.
Similarly, poor results and significant adverse effects have
been seen with mTOR inhibitors across several trials.62,63 It
is now well accepted that these failures result from inade-
quate inhibition of downstream signalling and positive
feedback loops following single agent therapy. First gener-
ation mTOR inhibitors, including temsirolimus and ever-
olimus, inhibit mTOR complex 1 (mTORC1) with little impact
on mTORC2 signalling. This may lead to compensatory
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continued activation of AKT, secondary to continued
mTORC2.64 Next generation agents which target both
mTORC1 and mTORC2 could circumvent the resistance
observed when targeting mTORC1 alone.64 Nevertheless,
trials which implement molecular discriminators to stratify
discrete subgroups of patients may hold promise; for
example, in a phase II RCT of newly diagnosed IDH-wt GBM
patients (NCT01019434), standard of care treatment was
compared with temsirolimus and radiotherapy.65 While
there was no significant improvement in OS and
progression-free survival (PFS), hypothesis-generating sub-
set analysis indicated that a small cohort of patients (n ¼
13) with phosphorylated-mTORSer2448 who received tem-
sirolimus had a significantly increased OS when compared
with patients negative for phosphorylated-mTOR Ser2448
(17.8 months versus 13.1 months; P ¼ 0.007).65
Overall, however, the reasons for failure of receptor
tyrosine kinase-targeted therapy and other cytotoxic agents
are multifaceted. Amid promising novel therapies, it would
seem clear that monotherapy with targeted agents is un-
likely to yield success in IDH-wt GBM patients. This is mainly
due to diverse and adaptive intratumoural heterogeneity
and ever-changing cellular states. Shrewdly chosen combi-
natorial regimens which exert synergistic effects may prove
more successful.
Chimeric antigen receptor-T-cell therapy
Chimeric antigen receptor (CAR)-T-cell therapy has
contributed greatly to the recent impetus in immuno-
therapy strategies in cancer.66 Several impressive clinical
trial results in CD19-positive acute lymphoblastic leukaemia
and diffuse B-cell lymphoma led to Food and Drug
Administration (FDA) approval of CAR-T-cell therapy in
2017.67,68 To date, results in the GBM setting have been
variable; for example, Sampson et al.69 observed that CAR-
T-cell therapy in VM/Dk mice harbouring orthotopic
SMA560vIII tumours resulted in a long-term cure which was
maintained despite tumour rechallenge. Futhermore,
O’Rourke et al.70 provided evidence of CAR-T-cell-induced
alteration of the TME where EGFRvIII expression levels
decreased significantly in five of seven patients, and a
robust cytolytic effect was induced at the disease site.
Nevertheless, as evidenced in the ACT IV trial
(NCT01480479), loss of EGFRvIII expression was observed in
approximately 60% of patients irrespective of treatment59
suggesting that decreased expression of EGFRvIII is a com-
mon and naturally occurring event. Moreover, post infusion
specimens have revealed a compensatory increase in other
immunosuppressive markers in the TME such as IDO1,
transforming growth factor-b (TGFb), interleukin (IL)-10,
FOXP3 and PD-L1.70 This limits the further expansion of
implanted CAR-T cells, thus impairing a more prolonged
clinical response.
Nevertheless, to address the specific challenge posed by
the immunosuppressive landscape, a phase I study
(NCT03726515) is currently investigating EGFRvIII-directed
CAR-T-cell therapy in combination with pembrolizumab in
newly diagnosed MGMT-unmethylated GBM. In this
context, it is hypothesised that targeting PD1 may reverse
the immunosuppressive TME, causing increased CAR-T-cell
efficacy.71 IL-13 receptor alpha 2 (IL13Ra2) represents
another promising tumour-associated antigen target to
reverse the immunosuppressive TME via CAR-T-cell tech-
nology.72 This high affinity IL13 receptor is significantly up-
regulated in mesenchymal GBM compared with normal
tissue.71 Initial studies have successfully delivered CAR-T
cells targeting IL13Ra2 intracranially. While an antitumour
response has been elicited in a subset of patients, a survival
benefit could not be established, given the limited number
of patients (n ¼ 3).73 Most recently, a phase I clinical trial
targeting IL13Ra2 in combination with ICIs (ipilimumab and
nivolumab) in GBM is being investigated (NCT04003649). A
further phase I clinical trial studying the effects of CAR-T-cell
therapy targeting IL13Ra2 in recurrent/refractory malignant
glioma (NCT02208362) has also been initiated. Data from
these trials will provide important information on the
safety, feasibility and optimal delivery approach for CAR-T
cells and will assess the potential synergy between CAR-T-
cell therapy and immune checkpoint blockade.
Overall, phase III CAR-T-cell data are urgently awaited.
Furthermore, an improved understanding of GBM tumour
heterogeneity and the underlying biology of the immuno-
suppressive TME, along with the identification of new an-
tigen targets continues to be mandated.72,74
Oncolytic virus therapy
Oncolytic virus (OV) therapy has emerged as a novel
approach to circumvent the immunosuppressive TME. OVs
based on adenovirus, herpes simplex virus, measles virus,
reovirus, retrovirus, parvovirus, poliovirus and others have
been assessed in GBM trials. The allure of OVs lies in their
ability to selectively infect tumour cells having direct and
indirect antineoplastic effects. OV-induced immunogenic
cell death results in the direct release of pathogen- and
damage-associated molecular patterns as well as pro-
inflammatory cytokines, resulting in a massive recruitment
and activation of immune cells. Tumour-associated antigens
released from virally lysed cancer cells into the TME are
cross-presented to T cells by antigen-presenting cells
including dendritic cells and macrophages, or directly by the
tumour cells, leading to the establishment of tumour-
specific T-cell immunity. The adaptive immunity not only
attacks the infected tumour cells, but also uninfected or
distant disseminated tumour cells. Therefore, OVs have the
potential to convert immunologically inert tumours into
highly immune-reactive ones and induce potent, long-
lasting antitumour immune responses.75
Two OVs (DNX-2401 and PVS-RIPO) were recently granted
a fast-track designation by the FDA for expedited drug
review. DNX-2401 is an engineered tumour-selective
adenovirus. A phase I clinical trial was conducted in 37
patients with recurrent malignant glioma and 20% of
patients receiving a single intratumoural injection of
DNX-2401 survived more than 3 years from treatment.
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Analyses of post-treatment surgical specimens revealed
direct virus-induced oncolysis and tumour infiltration by
CD8þ and T-betþ cells.76 Cerebrospinal fluid samples from
DNX-2401-treated GBM patients in another phase I trial
revealed cytokine concentrations indicative of a pro-
inflammatory microenvironment and a prolonged shift of
the protumoural M2 macrophages toward pro-
inflammatory M1 in post-treatment resection tissue.77 The
efficacy of poliovirus-derived PVS-RIPO is also being studied
in GBM. Desjardins et al.78 carried out a phase I clinical trial
of recombinant poliovirus in 45 IDH-wt patients with
recurrent GBM. Some 21% of patients treated with polio-
virus OV were alive at 36 months in comparison with 4%
survival at 36 months in the historical control group. This
OV acts by selectively targeting the cell adhesion molecule
CD155,79 which is intimately involved in tumour immune
escape strategies. In particular, CD155 blockade has been
shown to enhance response to ICI.80 Analysis of the TCGA
and Repository for Molecular Brain Neoplasia Data (Rem-
brandt) databases revealed CD155 expression was highest
in GBM compared with lower grade gliomas. This CD155
overexpression was most pronounced in mesenchymal and
classical subtypes,79 suggesting that patient stratification
may further enhance treatment response rates for PVS-
RIPO. Indeed, a study testing oncolytic measles virus in
GBM xenografts identified constitutive interferon pathway
activation as an efficacy determinant. Validation of this
resistance profile in 10 GBM patients in a phase I trial
revealed that virus replication in patient tumours was
inversely correlated with expression of this resistance gene
signature.81
A recent phase III RCT has further combined a retroviral
and chemotherapeutic regime (Toca 511 and Toca FC) in
recurrent anaplastic astrocytoma and GBM (NCT02414165).
Toca 511 is a genetically modified retrovirus which encodes
for the cytosine deaminase gene. Cytosine deaminase in
turn converts the prodrug 5-flurocytosine (Toca FC) to the
cytotoxic compound 5-flurouracil in cells infected with Toca
511.82 Patients underwent surgical resection and were
randomised to either intracranial injection of Toca 511 fol-
lowed by oral Toca FC or standard of care (lomustine, TMZ
or bevacizumab) (NCT02414165). Unfortunately, the trial
failed to meet its primary end point with no OS benefit
evident in treatment arms (11.1 months versus 12.2
months; P ¼ 0.6154).83 Nevertheless, subgroup analysis
indicated a survival benefit in second recurrence patients
with IDH-mt and AA histology (Hazard Ratio ¼ 0.102, P ¼
0.009). This survival benefit was not evident in the IDH-wt
cohort. While further studies are needed, the potential of
OV to reverse the GBM immunosuppressive microenviron-
ment holds promise as an effective treatment, in particular
when patient stratification and/or combinations with other
immunotherapies can be implemented.
ICI therapy
Therapeutic targeting of immune checkpoint proteins via
ICIs has been associated with significant clinical benefit in
several malignancies.84 PD-L1 has been shown to be highly
expressed in IDH-wt GBM.85,86 Disappointingly, data from
two recent phase III RCTs, CheckMate-143 (NCT02017717)
and CheckMate-498 (NCT02617589), failed to show a sur-
vival benefit in both newly diagnosed and recurrent GBM
patients treated with nivolumab.87 Additionally, the more
recent CheckMate-548 phase III RCT (NCT02667587), which
evaluated the addition of nivolumab to standard of care in
MGMT methylated newly-diagnosed GBM, has failed to
meet its primary end point of PFS. OS data of this study are
pending.88
Despite disappointing outcomes from CheckMate-143
and CheckMate-498, recent work from Cloughesy et al.89
and Schalper et al.90 has yielded promise. A multicentre
RCT studied the impact of neoadjuvant and adjuvant anti-
PD-1 blockade in recurrent GBM patients who were
amenable to further surgical resection. Whilst patient
numbers were small and therefore not sufficiently powered
to assess survival impact, the neoadjuvant group demon-
strated improved antineoplastic immune responses and OS
rates (13.7 months versus 7.9 months). Further validation of
these results is now needed. Overall, the advantage of
commencing therapy in advance of surgery may lie in the
greater antigen load before tumour debulking, thus
fostering a stronger and more prolonged immune-
modulatory impact.89 Schalper et al. conducted a single-
arm phase II clinical trial (NCT02550249) to assess the
immune-biological effects of neoadjuvant and adjuvant
anti-PD1 blockade in 30 GBM patients.90 Investigation into
the changes in the immune microenvironment upon
administration of neoadjuvant nivolumab revealed that
nivolumab in a neoadjuvant setting promotes several anti-
tumour immune effects, including increased immune cell
infiltration, enhanced chemokine transcript expression and
greater T-cell antigen receptor diversity among TILs.90
Whilst ICI therapy has produced disappointing clinical re-
sults to date, it is possible that modifications to drug
sequencing protocols may optimise clinical efficacy. Indeed,
combination therapy with OV or neoadjuvant administra-
tion may allow priming of the immune system before ICI
boosting. This approach is being taken in different cancer
types91 including a GBM trial testing DNX-2401 with pem-
brolizumab (NCT02798406). ICI therapies may be further
augmented by the combination of a BRAF and MEK inhib-
itor in a three-armed approach, as discussed by Killock92 in
the melanoma setting. Likewise, priming PD-1 and PD-L1
with an mTOR or STAT3 inhibitor may facilitate a more
responsive environment for checkpoint inhibitors.93 A
recent review by Le Rhun et al. provides further discussion
on molecular targeted therapy in GBM and discusses the
necessity for redesigned clinical trials in this setting.94
A high tumour mutational burden is observed in
approximately 10% of recurrent GBM patients.95 It was
previously hypothesised that this hypermutant cohort may
be more responsive to immune checkpoint blockade,96 due
to their neo-antigen load and antigen-targeting T cells.97
Whilst IDH-wt GBM displays particularly low neo-antigen
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concentrations contributing to immunotherapy resistance,
it was thought that inducing the mutational state in a
subset of GBM patients might elicit an immune response to
checkpoint inhibition.97 It was also hypothesised that TMZ
could induce this hypermutant state upon recurrence, with
TMZ-induced hypermutations most commonly associated
with MGMT methylated gliomas with IDH mutations.97
Notwithstanding these assumptions, it has yet remained
unclear whether high mutational burden may support a
superior immune response to immune checkpoint blockade.
In an attempt to more accurately characterise the pheno-
typic and molecular features of hypermutated gliomas,
Touat et al.98 recently showed that a low PD-1 blockade
response rate was observed within a population of hyper-
mutant gliomas that emerged following TMZ treatment. As
such, it would seem that a TMZ-driven hypermutator
phenotype does not guarantee an immune response to PD-1
blockade, likely due to the concurrent presence of mismatch
repair deficits and the subclonal nature of emergent
neo-antigens. Indeed, pressure from alkylating agents alone
is likely insufficient to induce a hypermutated phenotype
which guarantees the response to immune checkpoint
blockade observed in other malignancies.98 Overall Touat
et al.98 have highlighted how disease-specific differences in
the mutational landscape impact tumour response to
immunotherapy.
Tumour treating fields
Tumour treating fields (TTF) has emerged as a novel thera-
peutic strategy in GBM, gaining recent FDA approval as an
adjuvant therapy for newly diagnosed GBM patients
following standard surgical resection and chemoradiation.99
A transducer, worn by the patient, exerts both direct and
indirect antineoplastic effects via continuous delivery of low
intensity alternating electric fields (200 kHz).The 100-300 kHz
range has been shown to selectively disrupt mitoses in
rapidly dividing cells including the disruption of tubulin and
septin complexes.100,101 The resulting impaired spindle
function leads to aberrant chromatin segregation.102
Overall, TTF has emerged as the only approach to elicit
improved OS in IDH-wt GBM in recent years.103 Stupp
et al.103 published data from a phase III RCT in 2017 which
studied effects of TTF addition to patients undergoing
standard chemoradiotherapy. When compared with stan-
dard of care alone, the addition of TTF improved both PFS
(6.7 months versus 4 months) and OS (20.9 months versus
16 months). This patient cohort was largely comprised of
IDH-wt GBM (92% TTF group versus 95% control group).
Nevertheless, the wider implementation of TTF has several
limitations. TTF cost remains a challenge with an average
monthly treatment cost of V21,000.99 Connock et al.104
showed that combining TTF with TMZ in newly diagnosed
GBM yielded a cost of approximately V500,000/year of life
gained and would necessitate a cost reduction of 85% to
become cost effective. In addition, users are required to
wear the device for approximately 18 h per day. Stupp
et al.103 reported a compliance rate of 75%, although this
was in newly-diagnosed patients. Despite these limitations,
optimisation of TTF in GBM treatment protocols remains an
active area of research. Herrlinger et al. published data from
a recent phase III RCT showing improved OS (48.1 months
versus 31.4 months) in newly diagnosed MGMT hyper-
methylated GBM patients when treated with lomustine and
TMZ in newly-diagnosed MGMT hypermethylated GBM.105
The combined treatment of TTF and lomustine/TMZ has
been shown to be safe and feasible in newly diagnosed
GBM patients.106 Two phase II clinical trials (NCT03405792,
NCT03430791) aimed at studying the impact of TTF when
delivered in combination with ICI in newly diagnosed and
recurrent GBM (rGBM) are currently recruiting.
Neurotrophic tropomyosin receptor kinase fusions and
BRAF alterations
Chromosomal rearrangements of neurotrophic tropomyosin
receptor kinase (NTRK) genes occur in a significant number
of GBM cases, leading to constitutively active chimeric re-
ceptors and oncogenic addiction. Gene fusions involving
NTRK1, NTRK2 or NTRK3 (encoding TRKA, TRKB and TRKC,
respectively) occur at varying frequencies in GBM, with
NTRK2 fusions the most commonly observed (up to 11% of
GBM). NTRK1 and NTRK3 are observed in <1% of
cases,107,108 These NTRK fusions drive ligand-independent
activation of the TRK, resulting in activation of a variety
of downstream cascades including RAS/RAF/MEK/ERK and
PI3K/AKT pathways, ultimately promoting tumour cell pro-
liferation and survival.109 To date, it has been shown that
overexpression of the neurofascin (NFASC)-NTRK1 fusion
gene in NIH 3T3 cells increases cell proliferation, colony
formation and tumour formation in a xenograft model.
Moreover, targeting NTRK1 fusion transcripts with RNAi
inhibits the proliferative phenotype of fusion gene-
expressing cells.110 While this effect was not recapitulated
with commercially available TRKA inhibitors (AZ-23,
GW441756 or CEP-701), these data suggest that the pres-
ence of an NTRK fusion contributes to initiation or main-
tenance of selected GBM tumours and might represent a
target of vulnerability in fusion-positive patients.110 Inter-
estingly, larotrectinib, a selective pan-TRK inhibitor, has
recently received FDA approval for use in cases of NTRK
fusion-positive tumours. The inhibitor was tested in three
basket trials (phase I, I/II and II; NCT02122913,
NCT02637687 and NCT02576431, respectively) which
included 14 patients harbouring primary CNS tumours. An
overall response rate of 36% (n ¼ 5) was demonstrated,
including 14% complete responses (n ¼ 2) and 21% partial
responses (n ¼ 3). While these data are encouraging, large-
scale studies in the GBM setting are now warranted. Next
generation therapeutics such as repotrectinib (ROS1, TRK
and ALK inhibitor) are also currently under investigation in
fusion-positive CNS malignancies (NCT04094610).111
A subset of GBM tumours have also been shown to
harbour mutations in v-Raf murine sarcoma viral oncogene
homolog B (BRAF). In particular, this alteration is observed
in the rarer IDH-wt epithelioid (eGBM) subtype, with
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BRAFV600 mutations present in greater than 50% of these
cases.112 To date, targeting of mutant BRAF signalling has
been studied in several trials, with both dabrafenib113 and
vemurafenib (NCT01524978)114 showing promise in a small
subset of BRAFV600 mutant tumours114,115; The VE-BASKET
study of BRAFV600 mutant, nonmelanoma cancers assessed
the effect of vemurafenib in n ¼ 24 patients with gliomas.
Vemurafenib treatment resulted in a durable antitumour
response in a cohort of IDH1/2 wt low-grade gliomas, with
the greatest effect seen in pleomorphic xanthoastrocytoma
patients (n ¼ 7). This positive antitumour response was not
reflected in the higher-grade gliomas (n ¼ 11) where only
one partial response and five cases of stable disease were
observed. Indeed, two cases of stable disease greater than 6
months were recorded, but no patient showed a complete
response. While these data suggest that vemurafenib has
utility in BRAFV600 mutant gliomas, responses observed
within the trial were variable and dependent on histological
subtype. Moreover, patients lacked additional genomic
characterisation which would be required to further inter-
rogate observed treatment response patterns. Neverthe-
less, BRAF may be a targetable oncogene in a small
subgroup of IDH-wt GBM patients. Further validation of this
approach is outstanding.114
FUTURE DIRECTIONS: IDENTIFYING NEW IDH-WT SPECIFIC
CONTEXTS OF VULNERABILITY
To date, several efforts have been made to study the mo-
lecular underpinnings of GBM using high-throughput single
‘omic profiling (whole genome sequencing, methylomics,
RNA sequencing, microarray methods, reverse phase pro-
tein array, mass spectrometry and deep metab-
olomics)12,14,116 with an aim to identify altered genetic and
epigenetic tumour landscapes, explore the differential
expression of mRNA and protein and identify new contexts
of vulnerability. However, a complete and systematic un-
derstanding of the complexities of disease heterogeneity
requires the generation and integration of multiple mo-
lecular profiles (multi-omics). These profiles may subse-
quently be interrogated using advanced network analyses
that include specific signalling pathways (Figure 4). Such
machine network topology information, analysis of master
regulators or mechanistic and stochastic modelling of
learning approaches serve two purposes: (i) classification
and integration of large amounts of diverse data sets; and
(ii) mechanistic analysis using ‘fine grained’ models that
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Figure 4. Proposed integrative systems medicine framework for precision
treatment in IDH-wild-type GBM.
Omics data are collected from genomic, proteomic, metabolomic, epigenomic,
immunomic, transcriptomic and single-cell analyses. Machine learning and arti-
ficial intelligence (AI) methods support the clustering, classification and inte-
gration of ’omics and clinical data resulting in the generation of prediction
profiles and novel contexts of vulnerability. Such a novel systems biomedicine
framework could identify new actionable pathways, biomarkers and therapeutic
targets in IDH-wt GBM. These therapeutic targets and novel combinatorial ap-
proaches will be interrogated in state of the art patient derived organoid (PDO)
and patient derived xenograft (PDX) models.
GBM, glioblastoma; KPS, Karnofsky performance score; tSNE, t-distributed
stochastic neighbor embedding; wt, wild-type.
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simulate biochemical pathways and allow prediction of
new drug targets, combinations and personalised treat-
ments. As discussed, novel multi-omic studies at the single-
cell level are also now emerging which allow for the
simultaneous integration of bulk gene expression, epi-
genomic, proteomic and metabolomic data thus providing
deeper insight into the cellular diversity and genetic het-
erogeneity present within the TME.25 In short, a major goal
of integrative ‘multi-omics’ is to identify combined vari-
ables or biomarkers from multi-omics data that can predict
phenotypic outcomes such as therapeutic responses and
prognosis in cancer patients associated with their IDH
status. This approach requires access to large, well-curated
datasets such as that generated by Brennan et al. (500
GBM tumours),117 the Rembrandt database (671 pa-
tients),118 Ivy Glioblastoma Atlas Project (Ivy GAP) cohort
(41 patients)119 or the Glioma Longitudinal Analysis
(GLASS) consortium (257 patients).120 Access to these
datasets is expected to unravel the complex interactions
between the genome, transcriptome, epigenome, metab-
olome and significantly improve the understanding of GBM
hierarchies.
In order to better exploit molecular subtypes for therapy
selection and optimise the use of existing drugs, we should
also exit the paradigm of ‘one marker fits one targeted drug
regimen’. We are actively working to refine the molecular
stratification of IDH-wt GBM from a functional perspective,
applying a systems approach for identifying targetable
contexts of vulnerabilities and biomarkers that will be
validated in state-of-the-art preclinical models. In a fully
integrated approach, the EC funded cross-sectoral European
training network ‘GLIOTRAIN’ (www.gliotrain.eu) is
currently leveraging genomic, transcriptomics (bulk and
single-cell), epigenomic and proteomic data (underpinned
by a novel computational modelling framework) to inter-
rogate TME, metabolic and immunological features of IDH-
wt tumours (Figure 4). The overall objective of GLIOTRAIN is
to identify and interrogate novel therapeutic strategies for
application in IDH-wt GBM while simultaneously unravelling
disease resistance mechanisms.
Conclusion
Targeting IDH-wt GBM remains one of the most difficult
challenges in oncology today due to several obstacles,
including the pervasiveness of signal transduction feedback
loops and pathway redundancy, effects of tumour hetero-
geneity on the positive selection of drug-resistant subclones
and an immunosuppressive TME. Elucidation of IDH-
dependent functional relationships, genetic interactions
and unique signalling dependencies are required to identify
more effective therapeutic strategies. Success will leverage
new knowledge gained from integrated bulk and single-cell
multi-omic studies which have already assigned GBM into
potentially targetable subtypes.12,14 Each IDH-wt subtype
may ultimately be defined by differing vulnerabilities which
could be targeted in the future according to the paradigm of
precision medicine.
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